Article
EULAR has published a 2025 update for physical activity recommendations for patients with osteoarthritis (OA) and rheumatoid arthritis (RA).
All News
Article
Malignancy rivals cardiovascular disease as a leading cause of death in patients with systemic autoimmune diseases. Chronic inflammation and immune dysregulation can drive oncogenesis, while antitumor immune responses can trigger autoimmune phenomena (paraneoplastic syndromes, checkpoint inhibitor-induced rheumatic disease).
Article
After the first tumour necrosis factor inhibitor (TNFi) failure, patients with active rheumatoid arthritis (RA) responded by switching to upadacitinib, compared to cycling to a second TNFi, adalimumab.
Dr. John Cush
Tweet
Are uveitis and psoriasis independently associated with greater spinal radiographic progression in ankylosing spondylitis? Test your knowledge in the latest RheumIQ quiz at https://t.co/N5rfozh757 https://t.co/PjY1iuLv0X
Dr. John Cush
Tweet
Danish registry study of truncal (2,260) vs superselective (3,810) vagotomy (1977-95) vs general popul. (10:1). Truncal incr. RA risk (aHR 2.62), but selective did not (aHR 1.05. Neither had effect on OA risk https://t.co/dqejtN9TwY https://t.co/R0OJZTxd5T
Dr. John Cush
Tweet
Sun Pharma buys out Organon w/ $11.75 billion buyout. Both generated $6.2 billion in 2025 sales. Organon spun off from Merck in 2021, specializes in women’s health and is top 7 in biosimilars. Sun is into dermatology, ophthalmology and oncology-dermatology. https://t.co/zb4hucTqCJ
Dr. John Cush
Tweet
Presented at AACE Annual Meeting, FREEDOM Real-World Study looked atypical femoral Fxs & found a low AFF risk - 24 AFFs w/ denosumab (0.89/1KPY) vs 397 AFFs w/ bisphosphonates (0.82/1KPY) but no active comparators & excluded pts w/ comorbidities. https://t.co/vRwkfHSXxh https://t.co/xzgC0D5ZTu
Dr. John Cush
Tweet
Smoking is most established environmental risk factor for RA- Dz risk, severity, & RA-ILD. Role of other airborne pollutants is mixed: particulate matter & nitrogen dioxide show inconsistent associations w/ RA https://t.co/Fkemc5hAUB
Dr. John Cush
Tweet
TRACE study of 90 axSpA pts Rx w/ either TNFi or secukinumab (150 or 300 mg)- at wk 56, 59% achieved clinical-remission & 43% achieved w56-MRI-remission (SPARCC) w/ benefits by wk 4. Predictors of clinical remission: ASDAS & BMI (@wk16); none @wk56 https://t.co/CEsAeRMvUE https://t.co/SfSAm3u4IM
Dr. John Cush
Tweet
Twofold Mortality in SLE
Despite declining incidence of lupus, mortality for SLE was twice that of controls in this large incident cohort study.
https://t.co/Sv7XMnLT3J https://t.co/CURPZ5cYgt
Dr. John Cush
Tweet
Obesity is more than comorbidity—it’s a driver of inflammation.
At #RheumNowLive 2026, Dr. Uzma Haque breaks down weight management strategies that actually move the needle in rheumatology care.
🎧 Listen here: https://t.co/A6fbPvV2tD
#Rheumatology #Inflammation #Obesity https://t.co/RLxV44SrUB
Dr. John Cush
Tweet
Arthralgia w/ HIGH ACPA level >3x ULN) has a 30–50% probability of being diagnosed with RA within 3–5 years https://t.co/iJTyMQM480
Dr. John Cush
Tweet
FDA has accepted Genetech application for obinutuzumab (Gazyva) to treat SLE (currently only approved for lupus nephritis) - based on Phase III ALLEGORY study w/ Gazyva showing signif reduced dz activity https://t.co/louTYyN6bN https://t.co/Hy1gGliamn
Dr. John Cush
Tweet
“Success is not final, failure is not fatal: it is the courage to continue that counts.”
– Winston Churchill
Dr. John Cush
Tweet
https://t.co/4UQlqwujiR 2026 brought together leading rheumatology experts for two days of practical, clinically focused education.
Now you can watch the full program On Demand.
Highlights include:
• RA mortality trends and the mucosal hypothesis
• IL-23 vs IL-17 inhibitor https://t.co/YMfxa7PDXF
Dr. John Cush
Tweet
Comorbidity burden, uveitis, & psoriasis independently assoc w/ greater spinal radiographic progression in AS. Study3,441 pts (75% male; 84% B27+). Progression greater w/ 2+ comorbidities & uveitis, & PSO https://t.co/7Zh5SlMKc0 https://t.co/lmonP5YrcV
Dr. John Cush
Tweet
Rheumatology Salaries 2025
Medscape has published its annual Physician Compensation report with physican salaries up roughly 3% and eight specialties earning more than $500,000 per annum.
https://t.co/DNe42EsxRW https://t.co/aegcNm8Pla
Dr. John Cush
Tweet
Severe thrombocytopenia (TP) assoc w/ severe APS & increased mortality. Retro study of 432 #APS pts - 142 w/ TP (33%): 13% severe TP (<50L G/L). Severe TP assoc w/ ITP & CAP -had higher mortality https://t.co/7f8VpIcEJy
Dr. John Cush
Tweet
Weight-loss drugs may affect joints directly
A new study from Aarhus University shows that the hormone GLP-1, which is mimicked in medication for diabetes and weight loss, is present in joint fluid. In the long term, this may open up new treatments for arthritis. https://t.co/HkcPUQp05H
